Publications by authors named "Meir Schechter"

Claim this Profile
N
Neurodegeneration onset with glucagon-like peptide-1 receptor agonists in people with type 2 diabetes: a real-world multinational cohort study.
Meir Schechter, Alisa Fishkin, Ofri Mosenzon, Dvora R Sehtman-Shachar, Tali Cukierman-Yaffe

Cardiovasc Diabetol· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mortality, kidney, and safety outcomes with SGLT2 inhibitors versus DPP4 inhibitors in patients with type 2 diabetes treated with systemic glucocorticoids: a real-world exploratory study.
Meir Schechter, Yovel Cohen, Alisa Fishkin, Ofri Mosenzon, Gil Leibowitz

Diabetes Res Clin Pract· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists Versus Other Glucose-Lowering Agents in People With Type 2 Diabetes: A Systematic Review and Meta-Analysis of Real-World Data.
Alisa Fishkin, Aliza Rozenberg, Meir Schechter, Dvora R Sehtman-Shachar, Genya Aharon-Hananel

Diabetes Metab Res Rev· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Drug adherence, glycemic control, and weight reduction with subcutaneous semaglutide in real-world management of type 2 diabetes.
Cheli Melzer Cohen, Ofri Mosenzon, Alona Aharonovich, Avraham Karasik, Meir Schechter

Diabetes Res Clin Pract· April 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Normoalbuminuria-is it normal? The association of urinary albumin within the 'normoalbuminuric' range with adverse cardiovascular and mortality outcomes: A systematic review and meta-analysis.
Dvora R Sehtman-Shachar, Ilan Yanuv, Meir Schechter, Alisa Fishkin, Genya Aharon-Hananel

Diabetes Obes Metab· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and Safety of Dapagliflozin in Patients With Chronic Kidney Disease Across the Spectrum of Frailty.
Priya Vart, Jawad H Butt, Niels Jongs, Meir Schechter, Glenn M Chertow

J Gerontol A Biol Sci Med Sci· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Post hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.
Kam Wa Chan, J David Smeijer, Meir Schechter, Niels Jongs, Priya Vart

Kidney Int· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Risk of hospitalization with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes lacking evidence of chronic kidney disease: Real-world data.
Meir Schechter, Cheli Melzer Cohen, Tamir Zelter, Ilan Yanuv, Aliza Rozenberg

Diabetes Obes Metab· October 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease.
Cheli Melzer Cohen, Meir Schechter, Aliza Rozenberg, Ilan Yanuv, Dvora R Sehtman-Shachar

Clin J Am Soc Nephrol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease.
Meir Schechter, Glenn M Chertow, Hiddo J L Heerspink

Ann Intern Med· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin and Anemia in Patients with Chronic Kidney Disease.
Akihiko Koshino, Meir Schechter, Glenn M Chertow, Priya Vart, Niels Jongs

NEJM Evid· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence.
Meir Schechter, Cheli Melzer Cohen, Alisa Fishkin, Aliza Rozenberg, Ilan Yanuv

Cardiovasc Diabetol· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
Meir Schechter, Stephen D Wiviott, Itamar Raz, Erica L Goodrich, Aliza Rozenberg

Lancet Diabetes Endocrinol· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study.
Orit Kliuk-Ben Bassat, Meir Schechter, Natalia Ashtamker, Ilan Yanuv, Aliza Rozenberg

Clin Kidney J· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease : A Post Hoc Analysis of DAPA-CKD.
Meir Schechter, Niels Jongs, Glenn M Chertow, Ofri Mosenzon, John J V McMurray

Ann Intern Med· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS.
Akihiko Koshino, Meir Schechter, Taha Sen, Priya Vart, Brendon L Neuen

Diabetes Care· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.
Ofri Mosenzon, Itamar Raz, Stephen D Wiviott, Meir Schechter, Erica L Goodrich

Diabetes Care· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preventing all-cause hospitalizations in type 2 diabetes with sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A narrative review and proposed clinical approach.
Meir Schechter, Matan Fischer, Ofri Mosenzon

Diabetes Obes Metab· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults.
Meir Schechter, Cheli Melzer Cohen, Ilan Yanuv, Aliza Rozenberg, Gabriel Chodick

Cardiovasc Diabetol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of lifestyle intervention on cardiometabolic risk factors in mental health rehabilitation hostel residents at-risk: a cluster-randomized controlled 15-month trial.
Faina Tsodikov, Meir Schechter, Rebecca Goldsmith, Lilach Peleg, Vered Baloush-Kleinman

Int J Obes (Lond)· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prediction of the Effects of Liraglutide on Kidney and Cardiovascular Outcomes Based on Short-Term Changes in Multiple Risk Markers.
Sok Cin Tye, Sieta T de Vries, Johannes F E Mann, Meir Schechter, Ofri Mosenzon

Front Pharmacol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Loss of Corticostriatal Mu-Opioid Receptors in α-Synuclein Transgenic Mouse Brains.
Jessica Grigoletto, Meir Schechter, Ronit Sharon

Life (Basel)· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[IMPROVEMENT OF RENAL OUTCOMES WITH SODIUM-GLUCOSE COTRANSPORTER-2 (SGLT2) INHIBITORS].
Meir Schechter, Ofri Mosenzon

Harefuah· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence.
Meir Schechter, Cheli Melzer-Cohen, Aliza Rozenberg, Ilan Yanuv, Gabriel Chodick

Cardiovasc Diabetol· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kidney Outcomes With Glucagon-Like Peptide-1 Receptor Agonists in Patients With Type 2 Diabetes.
Ofri Mosenzon, Meir Schechter, Gil Leibowitz

Adv Chronic Kidney Dis· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis